Document:

EXHIBIT 10.6

                                LICENSE AGREEMENT

         This License Agreement ("AGREEMENT") is made and entered into effective
as of the 7th day of October, 1999, ("EFFECTIVE DATE") by and between RE-TRACK
USA, INC., a Delaware corporation ("LICENSOR"), and P. ROWAN SMITH, JR., an
individual, or his designee ("LICENSEE").

                                   WITNESSETH:

         WHEREAS, Licensor is the owner by assignment and otherwise of all
right, title and interest in and to those certain patent rights (defined below)
covering improvements in disposable retractable hypodermic syringes (more
particularly described below); and

         WHEREAS, Licensee desires to obtain an exclusive license of such patent
rights from Licensor to manufacture, produce, use, market, promote, transport,
distribute and sell disposable retractable hypodermic syringes containing
improvements covered by such patent rights; and

         WHEREAS, Licensor agrees to grant Licensee an exclusive license of such
patent rights for the stated purposes to Licensee on the terms and conditions
provided herein.

         NOW, THEREFORE, in consideration of the sum of TEN AND NO/100 DOLLARS
($10.00), the mutual agreements and covenants contained herein, and other good
and valuable consideration, the receipt of which is hereby acknowledged and
confessed, Licensor and Licensee agree as follows:

         1. DEFINITIONS. As used herein, the term:

                  (a) "GEOGRAPHIC TERRITORIES" shall mean the following named
sovereignties, kingdoms, nations or territories within the identified Continent
or geographic region:

                           (i) AFRICA: All nations, emirates, protectorates,
territories and/or sovereignties located within the continent of Africa.

                           (ii) ASIA: China, India and Pakistan;

                           (iii) EUROPE: Denmark, Finland, Norway and Sweden;

                           (iv) MIDDLE EAST: Israel, Iran, Iraq, Jordan, Oman,
Saudi Arabia, Syria, Turkey, the United Arab Emirates and Yemen;

                           (v) NORTH AMERICA, CENTRAL AMERICA, SOUTH AMERICA:
Argentina, Bolivia, Brazil, Chile, Columbia, Equador, French Guyana, the
Falkland Islands, Guyana, Mexico, Paraguay, Peru, Suriname, Uruguay and
Venezuela;

<PAGE>

                  (b) "RETRACTABLE SYRINGE(S)" shall mean a disposable
hypodermic medical syringe which contains a retractable hypodermic needle and is
the subject of the patent rights defined below.

                  (c) "PATENT RIGHTS" shall mean:

                           (i) United States Patent Nos.: (a) 4,790,822; (b)
4,950,251; (c) 5,152,750; (d) 5,342,323; (e) 5,453,093; and (f) those foreign
Letters Patent and Applications for foreign Letters Patent identified on EXHIBIT
A attached hereto and incorporated herein by reference for all purposes assigned
to Licensor and all other Letters Patent owned by Licensor or under which
Licensor now has or at any time may have the right to grant licenses, which are
related to the Retractable Syringes or derived from the technology described in
the aforementioned Letters Patent;

                           (ii) All Letters Patent owned by Licensor, or under
which Licensor now has or at any time may have the right to grant licenses,
which correspond to the foregoing international or United States Letters Patent;

                           (iii) All patent applications and resulting patents
filed or to be filed by Licensor claiming priority from or based on the
aforesaid international or United States Letters Patent;

                           (iv) All divisions, reissues, and extensions of the
items listed in Section 1.(c)(i), (ii) and (iii) above now or subsequently owned
by Licensor or under which Licensor now has or may subsequently have the right
to grant licenses; and

                           (v) All additions, modifications and advances made to
the patents described in Section 1.(c)(i) above.

                  (d) "NET SELLING PRICE" shall mean Licensee's gross selling
price for Retractable Syringes in their fully assembled form less any of the
following:

                           (i) All sales or excise taxes paid directly or
indirectly by Licensee;

                           (ii) All shipping costs separately itemized by
Licensee;

                           (iii) All normal and customary trade discounts,
returns and allowances; and

                           (iv) The sales price for Retractable Syringes paid by
Licensor to Licensee pursuant to Section 6 of this Agreement.

                                       2
<PAGE>

         2. GRANT. Upon the terms, royalty payments and conditions set forth
herein, Licensor agrees to GRANT, DELIVER and CONVEY to Licensee and hereby does
GRANT, DELIVER and CONVEY to Licensee an exclusive license to and under the
Patent Rights to manufacture, produce, use, market, promote, transport,
distribute and sell Retractable Syringes containing improvements covered by the
Patent Rights throughout the Geographic Territories.

         3. TECHNICAL DATA, INFORMATION AND OTHER MATERIALS. Licensor, at its
sole cost and expense, shall provide, or cause to be provided, to Licensee all
technical data, information and other materials associated with the Patent
Rights or appurtenant thereto in Licensor's possession or control that may be
necessary or required by Licensee in order to manufacture, produce, use, market,
promote, transport, distribute and sell Retractable Syringes as contemplated by
this Agreement. Additionally, Licensor shall make available and deliver to
Licensee all modifications, enhancements and improvements of and to the Patent
Rights made or caused to be made by Licensor prior to or after the execution of
this Agreement.

         4. ROYALTY. Licensee agrees to pay Licensor a royalty (the "10%
ROYALTY") equal to ten percent (10%) of the Net Selling Price of each
Retractable Syringe which is manufactured, assembled and sold anywhere in the
Geographic Territories by or for Licensee. It is understood and agreed that
Licensee shall pay the 10% Royalty for each Retractable Syringe sold by or for
Licensee, either alone or incorporated into subassemblies or finished products.
The 10% Royalty shall accrue when a Retractable Syringe (in whatever form) is
actually sold by Licensee. A Retractable Syringe is deemed sold at the time that
the invoice therefor is paid fully to Licensee.

                  During the first five (5) years of the Primary Term (as
defined below) the 10% Royalty shall be payable in arrears by Licensee to
Licensor annually and shall be due within sixty (60) days after the expiration
of each consecutive twelve (12) month period following the Effective Date for
which annual period such 10% Royalty is owed. Thereafter (and during any
applicable renewal period) the 10% Royalty shall be payable in arrears by
Licensee to Licensor semi-annually and shall be due within sixty (60) days after
the expiration of each six (6) month period thereafter. Within sixty (60) days
of the end of each respective and applicable accounting period throughout the
Primary Term of this Agreement (and any applicable renewal period), Licensee
shall furnish Licensor with a written statement, certified by a duly authorized
representative of Licensee, stating the value of the Retractable Syringes sold
in the preceding accounting period and setting forth the essential information
concerning the sales by Licensee of all Retractable Syringes subject to the 10%
Royalty and upon which the 10% Royalty is calculated. Such information shall
include the Net Selling Price of each Retractable Syringe licensed hereunder,
the quantity of Retractable Syringes sold, the form of the Retractable Syringes
sold, the place of manufacture of the Retractable Syringes sold, and all other
facts necessary to facilitate verification of the calculation of the 10% Royalty
and the identification of Retractable Syringes for which such royalties have
been paid by Licensee. Payment of the 10% Royalty shall accompany each such
statement.

                  Licensee agrees that it will at all times keep complete, true
and correct books of account containing a current record of sales and other data
in sufficient detail to enable the 10% Royalty payable under this Agreement to
be computed and verified. Licensee further agrees to permit an independent
certified public accountant, acceptable to Licensee, at Licensor's sole cost, to
have access for inspection of said books of account at Licensee's principal
place of business and at reasonable intervals during business hours.

                                       3
<PAGE>

                  The 10% Royalty due hereunder shall be paid in United States
Dollars. All royalties for an accounting period computed in other currencies
shall be converted into United States Dollars at the buying rate for the
transfer of such other currencies to United States Dollars as quoted by the
Chase Manhattan Bank on the last day of such accounting period, or the business
day thereafter if such last day shall be a Sunday or a holiday.

                  In the event any national government imposes any taxes on any
part of the payments required hereunder by Licensee to Licensor and requests
Licensee to withhold taxes from such payment, Licensee may deduct such taxes
from such payments. Tax receipts indicating payments or withholding of taxes on
behalf of Licensor shall be promptly submitted to Licensor. Licensee shall
cooperate with Licensor in a determination of the propriety of imposition of any
such tax.

                  In the event any national government imposes any exchange
restriction prohibiting payments as required under this Agreement, an account in
the name of Licensor shall be established in a financial institution of
Licensor's choice in the country of such national government and all monies due
Licensor shall be paid into such account, or at Licensor's election, payment
shall be made to any account designated by Licensor that complies with such
restriction.

         5. MARKING. Licensor agrees that Licensee shall have no obligation to
mark the Retractable Syringes in any manner which would indicate the nature of
the relationship between Licensee and Licensor created by this Agreement or
identifying Licensor, or any of its successors, as the registered owner of the
Patent Rights.

         6. LICENSOR'S RIGHT TO PURCHASE RETRACTABLE SYRINGES. Licensor may, at
its option, purchase from Licensee up to ten percent (10%) of all Retractable
Syringes which are manufactured annually by Licensee, on a non-cumulative basis,
at the actual cost incurred by Licensee to manufacture the Retractable Syringes
plus seven percent (7%) of such cost together with (a) all sales or similar tax
applicable thereto, (b) all special cost to package the Retractable Syringes
according to Licensor's specifications, and (c) all freight and shipment
charges. Licensor's rights granted under this Section 6 are non-transferable,
directly or indirectly, without the Licensee's prior written consent, and
Licensor covenants and agrees not to market, sell or distribute the Retractable
Syringes purchased from Licensee anywhere within the Geographic Territories.
Notwithstanding anything in this Agreement to the contrary, all proceeds from
the sale of Retractable Syringes to Licensor in accordance with this Section 6
shall be excluded from the calculation of the 10% Royalty otherwise payable to
Licensor by Licensee pursuant to Section 4 of this Agreement.

                                       4
<PAGE>

         7. DURATION AND TERM OF AGREEMENT. Unless otherwise terminated as
hereinafter set forth, this Agreement and the licenses under Patent Rights shall
continue in full force and effect for a period often (10) years following the
Effective Date this Agreement. If Licensee shall at any time default in
rendering any of the statements required hereunder, in the payment of any monies
due hereunder, or in fulfilling any of the other obligations hereof, and such
default shall not be cured within thirty (30) days after written notice thereof
is given by Licensor to Licensee, Licensor shall have the right to terminate
this Agreement by giving written notice of termination to Licensee; this
Agreement thereby being terminated fifteen (15) days after such notice of
termination is mailed by Licensor. If Licensor shall at any time default in
fulfilling any of its obligations herein and such default shall not be cured
within thirty (30) days after written notice thereof is given by Licensee to
Licensor, Licensee shall have the fight to terminate this Agreement by giving
written notice of termination to Licensor; this Agreement thereby being
terminated fifteen (15) days after such notice of termination is mailed by
Licensee. The waiver of any default under this Agreement by either party shall
not constitute a waiver of the right to terminate this Agreement for any
subsequent or like default, and the exercise of the fight of termination shall
not impose any liability by reason of termination nor have the effect of waiving
any damages to which the terminating party might otherwise be entitled.

                  In addition to the foregoing, Licensor shall have the right to
terminate this Agreement by giving written notice of termination to Licensee in
the event of the occurrence of any one of the following, such termination being
effective upon the earlier of Licensee's receipt of such notice or five (5) days
after such notice is mailed to Licensee: (i) the liquidation of Licensee; (ii)
the insolvency or bankruptcy of Licensee, whether voluntary or involuntary; or
(iii) the appointment of a trustee or receiver for the benefit of Licensee.

                  Notwithstanding any provision of this Agreement to the
contrary, Licensee may, with or without cause, terminate this Agreement upon
thirty (30) days prior written notice of termination to Licensor.

                  Termination of this Agreement for any cause whatsoever, shall
in no manner interfere with, affect or prevent the collection by Licensor of the
10% Royalty which may have accrued and be due to Licensor under the terms of
this Agreement. Upon termination of this Agreement for any reason, Licensee's
payment of the 10% Royalty required by Section 4, if any, but not yet due and
required by Section 4 to be paid shall be made on or before the next succeeding
regularly scheduled accounting and payment date as provided in Section 4 of this
Agreement as though termination of this Agreement had not occurred.

         8. LICENSEE'S OPTION TO RENEW AND RENEWAL FEE. Licensor grants to
Licensee an option to renew and extend the term of this Agreement for additional
one (1) year periods (singularly, the "RENEWAL PERIOD") perpetually and
continuously on an annual basis commencing on the expiration of the Primary Term
and each succeeding Renewal Period thereafter so long as Licensee is not in
default of its obligations under this Agreement at the time of the exercise by
Licensee of the relevant renewal option. Each Renewal Period shall be on the
terms and conditions of this Agreement in all respects. Licensee's renewal
option shall be exercisable by Licensee's by providing Licensor written notice
of Licensee's intent to exercise the renewal option at least thirty (30) days
prior to the expiration of the Primary Term or any subsequent Renewal Period and
concurrently therewith paying Licensor a renewal fee of TWENTY-FIVE THOUSAND AND
NO/100 DOLLARS ($25,000.00). If Licensee fails to timely exercise its option to
renew and extend the term of this Agreement this Agreement will terminate on the
expiry date of the then current term.

                                       5
<PAGE>

         9. LICENSOR'S REPRESENTATIONS AND WARRANTIES. Licensor, as a material
consideration and in order to induce Licensee to enter into this Agreement
hereby certifies, represents and warrants to Licensee as of the Effective Date
as follows:

                  (a) TITLE. Licensor is the lawful owner of the Patent Rights
and has good, indefeasible title to the Patent Rights free and clear of all
liens, encumbrances, leases, licenses and agreements of any kind and owns all
rights and interests appurtenant to the Patent Rights including, without
limitation, any trademark rights of any kind relating to the Patent Rights or
any derivative thereof (whether filed of public record or acquired by prior
usage) in accordance with any state or federal statute or common law;

                  (b) LICENSOR'S AUTHORITY. The license of the Patent Rights,
and all rights and interests appurtenant thereto, to Licensee has been duly
authorized by requisite corporate action and is enforceable and binding against
Licensor in all respects; the execution and delivery of this Agreement does not
constitute a violation or breach by Licensor of any provision of any agreement
or other instrument to which Licensor is a party or to which Licensor may be
subject although not a party, or will result in or constitute a violation or
breach of any judgment, order, writ, junction or decree issued against or
binding upon Licensor or the Patent Rights;

                  (c) NO COMPETING RIGHTS. No person, firm or entity, other than
Licensee has any right to license, purchase, or otherwise acquire or possess the
Patent Rights from Licensor. Licensor further warrants and represents that the
Retractable Syringes and parts and subassemblies thereof may be manufactured,
produced, used, marketed, promoted, transported, distributed and sold by
Licensee throughout the Geographic Territories as contemplated by this Agreement
free of patent rights or proprietary rights of others;

                  (d) NO PENDING PROCEEDINGS. There is no action, suit,
proceeding or claim affecting the Patent Rights, or any rights or interests
appurtenant thereto, nor affecting Licensor and relating to the ownership, use
or enjoyment of the Patent Rights pending or being prosecuted in any court or by
or before any federal, state, county or municipal department, commission, board,
bureau or agency or other governmental entity nor is any such action, suit,
proceeding or claim threatened or asserted; and

                  (e) PRESERVATION OF PATENT RIGHTS. Licensor has, prior to and
through the Effective Date, secured, preserved and maintained the Patent Rights,
including all registrations and qualifications that are necessary and proper or
otherwise are required by law, to prevent the use of the Patent Rights by third
parties or the infringement of the Patent Rights by third parties, or the
forfeiture of the Patent Rights.

                                       6
<PAGE>

         10. PROTECTION OF PATENT RIGHTS. Throughout the Primary Term and any
Renewal Period, Licensor will apply for, perfect, obtain and/or otherwise
refile, in all applicable jurisdictions, for all patents, modifications,
enhancements, improvements, and other related intangible rights with respect to
the Patent Rights and the Retractable Syringe technology, and will authorize and
empower Licensee, or its designee, to do so on its behalf and to take such other
and further action that may be necessary or desirable to apply for, perfect,
obtain and/or otherwise refile the same PROVIDED Licensee shall not be obligated
to incur or pay for any filing fees and/or related charges in connection with
such action in excess of SIX THOUSAND AND NO/100 DOLLARS ($6,000) in the
aggregate. Licensor agrees to cooperate with Licensee and to take all reasonable
steps necessary to prevent the infringement or suspected infringement of the
Patent Rights by any third party. In furtherance thereof, Licensee shall have
the right, in its sole discretion, to commence and prosecute with reasonable
diligence causes of action, whether at law or equity, against third parties for
infringement of the Patent Rights in its own name and in the name of Licensor,
and Licensor agrees to assist and cooperate fully with Licensee as Licensee may
reasonably request in connection with the prosecution of any such cause of
action. It is further understood and agreed by Licensor and Licensee that
Licensee shall be entitled to all damages, proceeds or recoveries resulting from
such causes of action.

         11. INDEMNITY. Licensor hereby agrees for itself and its successors and
assigns to indemnify, defend and hold harmless Licensee and Licensee's
shareholders, directors, officers, employees, agents, representatives,
successors, and assigns (collectively, "LICENSEE INDEMNIFIED PARTIES") from and
against any and all Claims (as herein defined) and Losses (as herein defined)
which the Licensee Indemnified Parties may suffer or incur as a result of or in
consequence of any claim of patent or other proprietary right infringement upon
the manufacture, production, use, marketing, promotion, transportation,
distribution and sale of Retractable Syringes by the Licensee Indemnified
Parties or the exercise of any other license right provided herein by the
Licensee Indemnified Parties and/or any alleged, purported or actual fraud or
other defalcation committed by Licensor with respect to any patent or other
proprietary right licensed hereunder to Licensee. For purposes hereof, the term
"CLAIMS" shall mean all claims, lawsuits, arbitrations, mediations, actions,
causes of action, and other legal actions and proceedings of whatever nature
brought against the Licensee Indemnified Parties based upon, in whole or in
part, any claim of patent or other proprietary right infringement upon the
manufacture, production, use, marketing, promotion, transportation, distribution
and sale of Retractable Syringes by the Licensee Indemnified Parties or the
exercise of any other license right provided herein by the Licensee Indemnified
Parties; and/or any alleged, purported or actual fraud or other defalcation
committed by Licensor with respect to any patent or other proprietary right
licensed hereunder to Licensee. For purposes hereof, the term "LOSSES" shall
mean all losses, costs, damages, expenses, judgments, and liabilities of
whatever nature directly or indirectly resulting from, arising out of, or
relating to the Claims, including, without limitation, attorney's fees, charges
and expenses, expert witness fees, charges and expenses, stenographer's fees,
charges and expenses, and all other fees, costs and expenses which the Licensee
indemnified Parties reasonably deems necessary to defend itself against the
Claims.

                                       7
<PAGE>

                  Licensor shall have the right to control the settlement of the
Claims if each of the following conditions are satisfied by Licensor: (a) the
full amount of any monetary settlement will be paid by Licensor; (b) a take
nothing judgment, or a non-suit, or a dismissal with prejudice is entered with
respect to Licensee; and (c) Licensee receives, as part of the settlement, a
release which is in form and substance reasonably satisfactory to Licensee,
providing that the Claims are fully settled and that Licensee is fully released
from any and all obligations or liabilities Licensee may have with respect to
the Claims.

                  Licensor covenants and agrees to reimburse Licensee within ten
(10) days of Licensor's receipt of written demand for all reasonable fees,
charges and expenses paid or payable by Licensee in connection with the defense,
satisfaction or settlement of the Claims. Licensee shall not settle or admit
liability to any Claims without the prior written consent of Licensor unless
Licensee elects to waive its rights to indemnity hereunder with respect to such
Claims or unless Licensor shall be in default of Licensor's obligations to
Licensee hereunder.

                  Any and all sums payable by Licensor to Licensee by virtue of
the indemnification in this Section 11 shall be paid to Licensee by certified or
cashier's check within ten (10) days of Licensor's receipt of written demand
therefor specifying in reasonable detail the sums so payable to Licensee.

         12. COMPETITION BY LICENSOR PROHIBITED. During the term of this
Agreement Licensor agrees not to engage directly or indirectly, whether as a
partner, owner, shareholder, director, or employee, in the manufacture,
production, use, marketing, promotion, transportation, distribution or sales of
any product in the Geographic Territories which contains improvements covered by
the Patent Rights or otherwise competes with any of Licensee's rights under this
Agreement. Licensor and Licensee acknowledge that the provisions of this Section
12 are reasonable in view of the consideration to be paid by Licensee pursuant
to this Agreement and the investment made and to be made by Licensee in the
business which is associated with the Retractable Syringes.

         13. CONFIDENTIALITY. Licensor and Licensee agree to maintain in strict
confidence all written or recorded information which is disclosed by one party
to the other in connection with this Agreement and specifically identified by
such party as being confidential ("CONFIDENTIAL INFORMATION"). Licensor and
Licensee shall not sell, transfer, publish, disclose, display or otherwise make
available such Confidential Information, or any part thereof, to any third party
without the express prior written consent of the other party. Licensor and
Licensee agree to secure and protect the Confidential Information in a manner
consistent with the requirements of this Agreement and to take appropriate
action by instruction or agreement with each party's respective employees or
consultants who are permitted access to the Confidential Information to satisfy
the obligations hereunder. Licensor and Licensee each acknowledges that the
other party will be irreparably harmed if the provisions of this Section 13 are
breached or violated by the other party and that neither party would have an
adequate remedy at law in the event of an actual or threatened violation by the
other party of its obligations herein. Therefore, Licensor and Licensee does
each agree and consent that the other party shall be entitled to an injunction

                                       8
<PAGE>

or any appropriate decree of specific performance for any actual or threatened
violation or breach of the provisions of this Section 13 by Licensor or Licensee
or their respective employees or agents without the necessity of showing actual
damages or that monetary damages would not afford and adequate remedy. The
foregoing remedy shall be in addition to any other remedy available at law or in
equity. It is understood and agreed by the parties hereto that the provisions of
this Section 13 shall not preclude disclosure by either party as may be
reasonably necessary: (i) to fulfill the purpose of the license granted herein,
(ii) to enforce such party's rights under this Agreement, or (iii) to comply
with a subpoena or other order of a court, provided however that the disclosing
party shall give the other party prompt notice of such subpoena or order and an
opportunity to contest the same.

         14. ASSIGNMENT BY LICENSEE NOT PROHIBITED. Notwithstanding anything in
this Agreement to the contrary, Licensee may assign, convey or otherwise
transfer its rights or interests in this Agreement and licensed use of the
Patent Rights as provided herein, or any portion thereof, to any third party
upon obtaining the written consent of Licensor, which consent shall not be
unreasonably withheld, conditioned or delayed. For the remainder of the Primary
Term only, Licensor shall continue to be entitled to receive from Licensee the
10% Royalty following any such transfer but shall not be entitled to any
additional royalty by reason of any such transfer by Licensee. As additional
consideration for Licensee's fight to assign or otherwise transfer its rights or
interests in this Agreement as provided herein, at the time of such transfer
Licensee shall pay to Licensor twenty percent (20%) of all front-end fees paid
by such transferee to Licensee related to such transfer.

         15. ARBITRATION. Any dispute, controversy or difference which may arise
between the parties out or in connection with this Agreement or for the breach
thereof may, by written agreement and consent of the parties, be submitted to
and resolved by arbitration in accordance with the Commercial Arbitration Rules
then in force of the American Arbitration Association. In accordance with the
written agreement of the parties executed prior to initiating any such
arbitration proceedings, the arbitration decision obtained may be final, binding
and conclusive against the parties in all respects, and judgment upon such
decision may be entered in any federal or state court of competent jurisdiction.
The parties shall share equally the fees, expenses and charges of the
arbitration, and each of them shall bear and pay its own attorney's fees
incurred in connection therewith except as otherwise provided herein.

         16. REMEDIES. Should Licensor default in the performance of, or
otherwise breach, its covenants, agreements, representations, warranties, and
other obligations provided herein, Licensee shall be entitled to exercise and
enforce all legal and/or equitable remedies that are available to Licensee by
reason of such breach or default, and the election and pursuit by Licensee of
any legal and/or equitable remedies, including, without limitation, specific
performance, shall not preclude Licensee from the election and pursuit of any
other remedies, whether set forth in this Agreement or authorized by law or
equity, notwithstanding any other provision set forth in this Agreement.
Licensor acknowledges that money damages would not be sufficient remedy for any
breach of Sections 2, 3, 12 and 13 of this Agreement by Licensor, and Licensee

                                       9
<PAGE>

shall be entitled to enforce the provisions of such Sections by terminating any
payments then owing to Licensor under this Agreement and/or to specific
performance and injunctive relief as remedies for such breach or any threatened
breach by Licensor. Such remedies shall not be deemed the exclusive remedies for
a breach of such Sections, but shall be in addition to all remedies available at
law or in equity to Licensee. It is specially understood, agreed and stipulated
by Licensor that Licensee shall not be required or otherwise obligated to post
or deposit any bond, surety or other similar undertaking as a requirement for
the enforcement of any remedies against Licensor, and in the event a court of
competent jurisdiction should require a bond, surety or other similar
undertaking as a condition to the enforcement of any remedies against Licensor,
Licensor further agrees and stipulates that the amount thereof shall not exceed
ONE THOUSAND AND NO/100 DOLLARS ($1,000).

         17. NON-WAIVER OF REMEDIES. The failure of any party at any time or
times to require performance by the other party of any provision hereof shall in
no manner affect the fight of such party thereafter to enforce the same, and the
waiver by any party of any breach of any provision hereof shall never be
construed to be a waiver of any succeeding breach of such provision or a waiver
of the provision itself.

         18. INDEPENDENT PARTIES. Nothing in this Agreement shall be deemed or
construed to constitute or create between Licensor and Licensee a partnership,
joint venture, or agency. This Agreement shall not cause Licensor to be the
legal representative or agent of Licensee, nor Licensee to be the legal
representative of or agent of Licensor. Except as expressly provided in this
Agreement, neither Licensor nor Licensee shall have the right or authority to
assume, create, or incur any liability or any obligation of any kind, express or
implied, against or in the name of or on behalf of another party.

         19. NOTICES. All notices, requests, demands and other communications
under this Agreement or in connection therewith shall be given to or be made
upon the respective parties at the following addresses:

                  To Licensee:
                                    Re-Track International, Inc.
                                    c/o Mr. P. Rowan Smith, Jr.
                                    16420 Park Ten Place, Suite 220
                                    Houston, Texas 77084
                  To Licensor:
                                    Re-Track USA, Inc.
                                    22 South Main Street
                                    New City, New York 10956
                                    Attn: Mr. Martin Kelly

         All notices, requests, demands and other communications given or made
in accordance with the provisions of this Agreement shall be in writing, shall
be delivered by certified or registered mail, return receipt requested, and
shall be deemed to have been given when deposited postage prepaid, with the
United States Postal Service addressed as specified above. Either party hereto
may change its address for Notice specified above by giving the other party ten
(10) days advance written notice of such change of address.

                                       10
<PAGE>

         20. SEVERABILITY. In the event that any of the provisions of this
Agreement shall be held invalid or unenforceable by any court of competent
jurisdiction, such invalidity or unenforceability shall not affect the remainder
of this Agreement and same shall be construed as if such invalid or
unenforceable provision had never been a part hereof.

         21. GOVERNING LAW. Licensor and Licensee each does hereby acknowledge
and stipulate that all negotiations and discussions pertaining to the subject
matter of this Agreement occurred in Houston, Harris County, Texas; each does
hereby acknowledge and stipulate that this Agreement has been executed and
delivered in the State of Texas and such execution and delivery shall be deemed
to be the transaction of business within the State of Texas; and each does
hereby covenant and agree that this Agreement shall be governed by the laws of
the State of Texas, and the rights and obligations of the parties thereto shall
be construed and interpreted in accordance with the laws of the State of Texas.

         22. JURISDICTION AND VENUE. Licensor and Licensee each does hereby
covenant and agree that jurisdiction and venue with respect to all actions and
proceedings instituted by either party to enforce this Agreement, or to
otherwise seek a declaration of rights under this Agreement, shall be in Harris
County, Texas, and any lawsuit filed and prosecuted in connection therewith
shall be exclusively in any State District Court of Harris County, Texas, or in
any United States District Court for the Southern District of Texas, Houston
Division. In the event any dispute or controversy arises between the parties out
of this Agreement, Licensor irrevocably appoints, authorizes and empowers the
Secretary of the State of Texas to act and serve as its agent for service of
process and citation with respect to any actions or proceedings filed by
Licensee against Licensor. Licensor unconditionally agrees that Licensee may
serve any judicial process or citation against Licensor in connection with such
actions or proceedings by delivering the same to the Secretary of the State of
Texas, in accordance with Tex. Civ. Prac. & Rem. Code Ann. ss. 17.041 ET SEQ.
(Vernon 1986), and requesting that such process or citation be forwarded to
Licensor by registered mail at the address provided herein. Licensor stipulates,
acknowledges and agrees that the method of service provided herein is reasonably
calculated, under all of the circumstances, to give actual notice of the
proceedings to Licensor in time to answer and defend.

         23. PARTIES BOUND. This Agreement and the provisions herein contained
shall be binding upon and inure to the benefit of each of the parties and their
respective successors and assigns.

         24. MODIFICATION AND AMENDMENT OF AGREEMENT. This Agreement may not be
modified or amended except by an agreement in writing signed by the parties
hereto. The parties may waive any of the conditions contained herein or any of
the obligations of the other party hereunder, but any such waiver shall be
effective only if in writing and signed by the party waiving such conditions or
obligations.

                                       11
<PAGE>

         25. ATTORNEYS' FEES. In the event it becomes necessary for either party
hereto to file a suit to enforce this Agreement or any provisions contained
herein, the party prevailing in such action shall be entitled to recover, in
addition to all other remedies or damages, reasonable attorney's fees incurred
in such suit.

         26. ENTIRE AGREEMENT. This Agreement constitutes the entire agreement
among the parties pertaining to the subject matter hereof and supersedes all
prior and contemporaneous agreements and understandings of the parties in
connection therewith. No representation, warranty, covenant, agreement or
condition not expressed in this Agreement shall be binding upon the parties
hereto or shall affect or be effective to interpret, change or restrict the
provisions of this Agreement.

         EXECUTED as of the Effective Date.
                                    LICENSOR:
                                    ---------

                                    RE-TRACK USA, INC.,
                                    A DELAWARE CORPORATION

                                    By: /S/ Martin Kelly
                                        ----------------------------------------
                                    Name:  Martin Kelly
                                          --------------------------------------
                                    Title: President
                                           -------------------------------------

                                    LICENSEE:

                                    P. ROWAN SMITH, JR.

                                    By: /S/ P. ROWAN SMITH
                                       -----------------------------------------
                                    Name: P. ROWAN SMITH
                                         ---------------------------------------
                                    Title:
                                           -------------------------------------

                                       12
<PAGE>

                                    EXHIBIT A
                                    ---------

COUNTRY                                      PATENT NO ./APPLICATION NO.
-------                                      ---------------------------
Australia                                    Patent No. 657,885

Belgium                                      Patent No. 0 388 137

Canada                                       Application No. 2,032,730-8

Europe                                       Application No. 92 91 1991.5
        (Austria, Belgium, France,
        Germany, Italy, Liechtenstein,
        Luxembourg, Netherlands, Portugal,
        Spain, Sweden, Switzerland, and
        United Kingdom)

France                                       Patent No. 0 388 137

Germany                                      Patent No. 690 09 248.2-08

Great Britain                                Patent No. 0 388 137

India                                        Application No. 854/Del/92

Italy                                        Patent No. 0 388 137

Japan                                        Application No. 401754/90

Korea                                        Application No. 3506/1990

Malaysia                                     Application No. PI 9201716

Mexico                                       Patent No. 173,117

Mexico                                       Patent No. 177,859

Netherlands                                  Patent No. 0 388 137

Sweden                                       Patent No. 0 388 137

Taiwan                                       Patent No. UN-76031

                                       13EXHIBIT 10.7

                              REDEMPTION AGREEMENT
                              --------------------

         AGREEMENT made August 17, 2000, by and between Retrac Medical, Inc., a
Delaware corporation (the "Corporation"), having an address at 22 South Main
Street, New City, New York 10956, and Martin C. Kelly (the "Seller"), residing
at 8 Bruce Court, Montebello, New York 10901.

         Whereas in order to effectuate an Initial Public Offering the
Corporation is effecting a two-for-three reverse stock split and

         Whereas upon the completion of this reverse stock split the Seller is
willing to sell four million of his shares to the Corporation for the sum of
$3,500,000.00, and

         Whereas the Corporation's Board of Directors has unanimously determined
that the amount of $3,500,000.00 is fair and that the offer of the Seller should
be accepted,

         Now therefore, in consideration of the premises, the parties agree as
follows:

         1. SURRENDER OF SHARES. Concurrently herewith, the Seller shall
surrender to the Corporation the certificates representing the four million
shares that he hereby agrees to sell. Each certificate shall be duly endorsed in
blank for transfer.

         2. REPRESENTATIONS. The Seller represents and warrants that he is the
sole owner of the four million shares of the Corporation, and that all of such
shares are free and clear of liens or encumbrances of any kind.

         3. PAYMENT OF REDEMPTION PRICE. The Corporation shall pay the Seller
for his shares over an eighteen month period as follows:

                  (a) $1,500,000.00 upon the breaking of escrow on the
Corporation's Initial Public Offering, and

                  (b) Commencing ninety days after such breaking of escrow, six
payments of $333,333.33, payable every ninety days pursuant to a demand note
executed concurrent herewith (copies of which are annexed hereto as Exhibit A).

         4. CONSULTING AGREEMENT. The Corporation hereby agrees to enter into a
consulting agreement with Seller. Said agreement shall be for a period of one
year, retroactive to August 1, 2000. Seller shall be compensated under said
agreement at a rate of $12,000.00 per month.

         5. EMPLOYMENT CONTRACT. The Seller hereby waives all rights and claims
that Seller may have against the Corporation pursuant to his terminated
employment contract, such termination effective retroactively to August 1, 2000,
including salary and benefits accrued, and the issuance of any additional shares
due, under said employment agreement.

                                       1
<PAGE>

         6. STOCK OPTIONS. The Corporation shall issue to Seller three hundred
thousand stock options allowing him to buy one share of the Corporation's stock
per option at 120% of the Initial Public Offering price of the Corporation's
stock. These options shall be exercisable for a three year period beginning one
year after the Corporation's Initial Public Offering. Said stock options shall
carry piggy-back registration rights.

         7. TIME LIMIT. In the event that the Corporation does not complete its
Initial Public Offering by March 1, 2001, the Seller has the right to unwind
this agreement. In that event, the Seller shall be entitled to keep all monies
paid to him up to that date under paragraph 4.

         8. PROXIES. All shareholder proxies that the Seller currently holds are
hereby made void retroactive to August 1, 2000.

         9. GENERAL RELEASE. Concurrently herewith, the Seller has executed a
general release, as against the directors of the corporation. A copy of said
release is annexed hereto as Exhibit B.

         10. NONDISCLOSURE AND CONFIDENTIALITY AGREEMENT. The Seller has
previously signed a nondisclosure and confidentiality agreement with respect to
certain confidential information and trade secrets belonging to the Corporation.
A copy of said nondisclosure and confidentiality agreement is annexed hereto as
Exhibit C.

         11. ENTIRE AGREEMENT. This Agreement constitutes the entire Agreement
between the parties with respect to its subject matter and may not be modified
or amended orally.

         12. NOTICES. All notices or other documents under this agreement shall
be in writing and delivered personally or mailed by certified mail, return
receipt requested, postage prepaid, addressed to parties at their last known
addresses.

         13. NON-WAIVER. No delay or failure by either party to exercise any
right under this Agreement, and no partial or single exercise of that right,
shall constitute a waiver of that or any other right, unless expressly provided
herein.

         14. HEADINGS. Headings in this Agreement are for convenience only and
shall not be used to interpret or construe its provisions.

         15. GOVERNMENT LAW. This Agreement shall be construed in accordance
with and governed by the laws of the State of New York State. In the event that
any dispute arises regarding either the terms and conditions of this agreement
or the performance of either of the parties pursuant thereto, the parties agree
that any litigation or alternative dispute resolution process regarding such
dispute shall be venued in the County of Rockland, State of New York.

         16. COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original but all of which
together shall be one and the same instrument.

         17. BINDING EFFECT. The provisions of this Agreement shall be binding
upon and inure to the benefit of each of the parties and their respective
successors and assigns.

                                       2
<PAGE>

         In witness whereof the parties hereto have caused this agreement to be
duly executed.

Corporate Seal

                                                   Retrac Medical, Inc.

Attest:

By: /S/ Alexander Mulgrew                          By: /S/ Thomas Sassone
    ----------------------------                       -------------------------
    Alexander Mulgrew, Secretary                       Thomas Sassone, President

                                                   /S/ Martin C. Kelly
                                                   ----------------------------
                                                   Martin C. Kelly

                                       3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}]]